SureNano Science Ltd. SURNF

Company Overview

SureNano Science Ltd. (OTC: SURNF) is a Canadian technology and applied sciences company focused on nanotechnology-based product development and commercialization. Public disclosures indicate the company has concentrated on nano-emulsion and delivery-system technologies designed to improve ingredient absorption, stability, and bioavailability across consumer and industrial applications. The company has explored opportunities in sectors including wellness, nutrition, and cannabinoid-related formulations, although the scope and commercial scale of these activities have varied over time based on corporate filings and market updates.

The company’s primary value proposition has centered on proprietary nano-encapsulation and emulsification capabilities intended to support enhanced ingredient delivery in liquids and consumable products. Available public information suggests SureNano has pursued strategic positioning as a technology platform provider rather than solely a branded consumer-products company. Historical disclosures indicate the company evolved through technology licensing, research and development initiatives, and partnerships intended to commercialize intellectual property and formulation technologies. Some operational and commercial details remain limited in publicly available filings, and certain claims regarding market penetration or commercialization status are inconclusive based on available public sources.

Business Operations

SureNano Science Ltd.’s operations have historically focused on the development and commercialization of nanotechnology-enabled formulations and related intellectual property. Public filings and investor materials reference activities involving nano-emulsion systems, ingredient delivery technologies, and product-development services. Revenue generation appears to have been tied primarily to technology commercialization efforts, licensing opportunities, strategic collaborations, and formulation-related services rather than large-scale manufacturing operations. Data regarding sustained recurring revenue streams or long-term commercial contracts is limited in publicly available disclosures.

The company has operated primarily from Canada, with efforts directed toward broader North American market opportunities. Public information references relationships and strategic collaborations associated with product development and commercialization, though details regarding long-term joint ventures, material subsidiaries, or large-scale international operating assets are limited. Available disclosures do not clearly establish a diversified multinational operating structure comparable to larger publicly traded technology or consumer-products companies.

Strategic Position & Investments

SureNano Science Ltd.’s strategic direction has emphasized the application of nanotechnology to improve product efficacy, absorption, and formulation performance. Publicly disclosed initiatives have included the development of proprietary delivery technologies and exploration of commercialization opportunities in wellness-oriented and science-based consumer markets. The company has also communicated interest in expanding intellectual property value through licensing arrangements and strategic partnerships.

Available filings and corporate updates indicate the company has pursued growth through technology development rather than through large-scale acquisitions. Publicly verifiable information regarding major acquisitions, significant portfolio holdings, or extensive subsidiary structures is limited. While the company has referenced emerging technology applications involving nano-delivery systems and advanced formulation science, the commercial maturity and scale of these initiatives are difficult to independently verify from currently available public disclosures.

Geographic Footprint

SureNano Science Ltd. is headquartered in Canada and has primarily focused on opportunities within the North American market. Public disclosures suggest the company has pursued commercial relevance in both Canada and the United States, particularly through OTC market participation and technology commercialization efforts. Its operational footprint appears relatively concentrated compared with larger multinational science or consumer-health companies.

The company’s international influence has largely been associated with intellectual property positioning and potential licensing opportunities rather than extensive physical operations across multiple continents. Data regarding substantial overseas facilities, manufacturing infrastructure, or direct operational control in major foreign markets is inconclusive based on available public sources.

Leadership & Governance

SureNano Science Ltd. has been managed by executives with backgrounds in business development, commercialization, and emerging technologies. Public company disclosures identify leadership responsible for overseeing technology strategy, investor relations, and corporate growth initiatives. The company’s governance approach appears focused on advancing proprietary technologies while seeking commercialization partnerships and market expansion opportunities.

Key executives identified in public disclosures include:

• Mark Scott – Chief Executive Officer
• Guy Geswein – Executive Chairman

Additional executive and governance information has varied across reporting periods, and some historical leadership records are inconsistent across publicly available sources. The company’s stated strategic vision has generally emphasized leveraging nanotechnology innovation to create differentiated formulation and delivery solutions across targeted consumer and industrial applications.